

Serena Vettori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/295600/publications.pdf>

Version: 2024-02-01

52
papers

2,576
citations

236612

25
h-index

189595

50
g-index

52
all docs

52
docs citations

52
times ranked

3359
citing authors

#	ARTICLE	IF	CITATIONS
1	Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSICIS trial compared with healthy reference subjects. <i>Respiratory Research</i> , 2022, 23, .	1.4	1
2	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 57-65.	1.0	8
3	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	0.9	14
4	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	2.5	43
5	T-Cell Proapoptotic and Antifibrotic Activity Against Autologous Skin Fibroblasts in vitro Is Associated With IL-17A Axis Upregulation in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 220.	2.2	10
6	Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. <i>British Journal of Pharmacology</i> , 2020, 177, 4296-4309.	2.7	19
7	Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis. <i>Scientific Reports</i> , 2019, 9, 9468.	1.6	26
8	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.5	142
9	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-6.	0.8	11
10	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	2.5	101
11	Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value. <i>Clinical Rheumatology</i> , 2018, 37, 1239-1247.	1.0	21
12	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.5	12
13	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	0.9	60
14	Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association. <i>PLoS ONE</i> , 2018, 13, e0210023.	1.1	5
15	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.5	132
16	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.5	410
17	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis,) Tj ETQq1 1 0.784314 rgBT /Overlock 11	2.5	107
18	The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score. <i>Arthritis Research and Therapy</i> , 2017, 19, 133.	1.6	21

#	ARTICLE	IF	CITATIONS
19	CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously) Tj ETQq1 1 0.784314 rgBT ₁₀ /Overl	1.9	10
20	Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases. Patient Related Outcome Measures, 2017, Volume 8, 7-13.	0.7	11
21	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.5	82
22	Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study. Clinical Rheumatology, 2016, 35, 1733-1742.	1.0	22
23	Serum CXCL4 increase in primary Sjögren's syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement. Clinical Rheumatology, 2016, 35, 2591-2596.	1.0	6
24	N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. International Journal of Cardiology, 2016, 223, 385-389.	0.8	16
25	Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. Medicine (United States), 2016, 95, e3931.	0.4	13
26	Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis. Clinical Rheumatology, 2016, 35, 1985-1991.	1.0	4
27	Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. Annals of the Rheumatic Diseases, 2016, 75, 303-310.	0.5	45
28	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 2016, 75, 1285-1292.	0.5	56
29	IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Annals of the Rheumatic Diseases, 2016, 75, 1697-1705.	0.5	48
30	Incidence and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE, 2016, 11, e0163894.	1.1	158
31	Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis. Clinical and Experimental Immunology, 2015, 181, 100-109.	1.1	13
32	Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. Seminars in Arthritis and Rheumatism, 2015, 44, 437-444.	1.6	51
33	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Annals of the Rheumatic Diseases, 2015, 74, 1124-1131.	0.5	96
34	High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. PLoS ONE, 2014, 9, e105008.	1.1	39
35	The Concept of Early Systemic Sclerosis Following 2013 ACREULAR Criteria for the Classification of Systemic Sclerosis. Current Rheumatology Reviews, 2014, 10, 38-44.	0.4	26
36	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1898-1904.	0.5	165

#	ARTICLE	IF	CITATIONS
37	Early Systemic Sclerosis: Analysis of the Disease Course in Patients With Marker Autoantibody and/or Capillaroscopic Positivity. <i>Arthritis Care and Research</i> , 2014, 66, 1520-1527.	1.5	48
38	Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. <i>Journal of Clinical Immunology</i> , 2014, 34, 663-668.	2.0	61
39	Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 673-680.	1.6	21
40	Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 23.	1.0	22
41	Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. <i>Arthritis Research and Therapy</i> , 2013, 15, R63.	1.6	38
42	A7.3â€¦Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A48.3-A49.	0.5	0
43	MiRs in RA: possible biomarkers and therapeutic targets. <i>Arthritis Research and Therapy</i> , 2012, 14, .	1.6	1
44	Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement. <i>Arthritis Research and Therapy</i> , 2012, 14, R188.	1.6	31
45	Role of MicroRNAs in Fibrosis. <i>Open Rheumatology Journal</i> , 2012, 6, 130-139.	0.1	144
46	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1178-1182.	0.5	30
47	Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. <i>Rheumatology</i> , 2011, 50, 317-323.	0.9	61
48	Non-Hodgkinâ€™s lymphoma in systemic sclerosis: case and literature review. <i>Clinical Rheumatology</i> , 2010, 29, 1-6.	1.0	14
49	Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role?. <i>Rheumatology</i> , 2010, 49, 1257-1266.	0.9	16
50	Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 485-489.	0.6	31
51	Association between a stromal cell-derived factor 1 (<i>SDF-1/CXCL12</i>) gene polymorphism and microvascular disease in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 408-411.	0.5	29
52	Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1210-1215.	0.5	25